Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers), Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers), SERT inhibitors(Serotonin transporter inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS Registry25332-39-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Neuropathies | Phase 2 | GB | 22 Nov 2018 | |
Diabetic Neuropathies | Phase 2 | PL | 22 Nov 2018 | |
Diabetic Neuropathies | Phase 2 | FR | 22 Nov 2018 | |
Diabetic Neuropathies | Phase 2 | CZ | 22 Nov 2018 |
Not Applicable | 318 | (fcfkjmpctc) = erugnboxpl kgcrncazrh (szxeyczszl ) | - | 03 Jul 2023 | |||
(fcfkjmpctc) = cokrudadvf kgcrncazrh (szxeyczszl ) |